9/14/2020 | IG | Market Commentary: Brookfield prices preferred units; First Republic gains; MFA Financial rises
|
9/14/2020 | PF | Market Commentary: Brookfield prices preferred units; First Republic gains; MFA Financial rises
|
9/14/2020 | PF | NuGenerex to price 13% cumulative redeemable preferred stock
|
9/14/2020 | PF | Generex to sell $33 million 13% cumulative redeemable preferreds
|
6/26/2015 | PP | Generex concludes $500,000 private placement of convertible preferreds
|
3/28/2014 | PP | Generex concludes $2.08 million sale of convertible preferred stock
|
1/15/2014 | PP | Generex completes $2.03 million sale of convertible preferred stock
|
6/18/2013 | PP | Generex concludes $1.23 million sale of convertible preferred stock
|
12/11/2012 | PP | Generex completes $750,000 placement of convertible preferred stock
|
8/8/2012 | PP | Generex negotiates $750,000 placement of convertible preferred stock
|
1/31/2012 | PP | Generex negotiates $2 million offering of convertible preferred stock
|
7/11/2011 | PP | Generex arranges $5.15 million offering of convertible preferred stock
|
1/25/2011 | PP | Generex orchestrates $6 million registered direct offering of stock
|
4/8/2010 | PP | New Issue: Generex arranges $23.37 million registered direct offering of stock
|
1/29/2010 | CVHY | Generex Biotechnology files $150 million stock and preferreds shelf
|
9/14/2009 | PP | New Issue: Generex orchestrates $12.25 million registered direct offering of stock
|
9/14/2009 | PP | Market Commentary: Navigator plans PIPE; Generex eyes direct offering; Commerce Resources wraps upsized units
|
8/6/2009 | PP | New Issue: Generex Biotechnology plans $5.65 million offering of stock, warrants
|
6/15/2009 | PP | New Issue: Generex Biotechnology seals $10.99 million direct offering of stock
|
5/18/2009 | PP | New Issue: Generex Biotechnology completes $5 million registered direct offering of equity
|
5/18/2009 | PP | Market Commentary: Generex announces direct offering; Apex closes stock deal; First Century wraps $4.9 million sale
|
4/6/2009 | PP | Generex satisfies obligations under forbearance agreement
|
3/27/2009 | PP | Generex once again extends 8% convertible notes forbearance agreement to April 3
|
3/20/2009 | PP | Generex extends 8% convertibles forbearance agreement to March 27
|
3/2/2009 | PP | Generex negotiates forbearance agreement in regard to 8% convertible notes
|
12/23/2008 | PP | Generex, investors agree to amend 8% convertibles to cure default
|
4/2/2008 | PP | New Issue: Generex secures $20.65 million from sale of convertible notes, warrants
|
4/2/2008 | PP | Market Commentary: MDwerks raises $7.5 million; Raptor, National Holdings sell to funds; Generex sells convertibles
|
11/6/2006 | BT | Generex begins phase 1 trials of synthetic avian flu vaccine
|
10/16/2006 | BT | Generex $52.5 million cash position sufficient for next 12 months
|
9/19/2006 | BT | Generex: Antigen Express technology used to detect type 1 diabetes
|
9/18/2006 | BT | Market Commentary: Genentech steady on Glaxo filing; Cell Therapeutics, Inovio gain on deals; MannKind up, Nektar down
|
9/15/2006 | BT | Generex posters highlight alternative insulin delivery
|
9/1/2006 | BT | Market Commentary: Sanofi flu news pushes smaller biotechs lower; BioDelivery off 10%; Curis slips on R&D shift
|
8/28/2006 | BT | Market Commentary: Discovery Partners up 9% on MedImmune, Infinity pact; EPIX plunges; Sinovac soars; PDL up
|
8/16/2006 | BT | Generex granted U.S. patent covering broad claims for drug delivery via the buccal cavity
|
8/8/2006 | BT | Generex adds prostate cancer patients to Antigen Express cancer vaccine trials
|
7/28/2006 | BT | Generex awarded two Japanese, one U.S. patent for Oral-lyn oral insulin product
|
7/27/2006 | BT | Market Commentary: Adams hit 4%; Conor slips after follow-on; Diomed pockets $10 million from PIPE; Oscient gains
|
7/26/2006 | BT | Generex presents data on its oral insulin spray, metformin gum products at meeting
|
7/26/2006 | BT | Market Commentary: DOV comes off highs; Neurocrine extends losses after hours; bird flu stocks fly; NicOx rises
|
7/10/2006 | BT | Generex says preclinical phase 1 studies show efficacy of antitumor vaccine
|
6/9/2006 | BT | Generex receives patent in Mexico for aerosol drug delivery
|
6/2/2006 | BT | Market Commentary: Encysive stock skyrockets on nod from European agency; Alphatec stock slips on IPO
|
6/2/2006 | PP | Market Commentary: Jed Oil wraps $34.33 million convertible offering; Jones Soda secures $30 million from stock sale
|
6/2/2006 | BTPP | New Issue: Generex raises $7 million from private placement of stock
|
5/24/2006 | BT | Market Commentary: Sirna, Minrad, AngioDynamics follow-on deals get off; bird flu vaccine names continue to climb
|
5/23/2006 | BT | Market Commentary: Sirna slides 8% ahead of reduced deal; Auxilium gains; Alnylam off; bird flu names up after hours
|
5/16/2006 | BT | Market Commentary: Neurocrine, DOV dive; Novavax, Generex dive amid noise of exits; Adventrx slips modestly on deal
|
5/2/2006 | BT | Generex releases positive data on Oral-lyn insulin replacement
|
4/10/2006 | BT | Generex Biotechnology announces positive interim results of oral insulin spray trial
|
3/27/2006 | BT | Market Commentary: Amylin drops 3% on follow-on; Keryx up 3% on PIPE; Cubist off; Cephalon off, Generex dives 20%
|
3/21/2006 | BT | Market Commentary: Novavax, Nastech buck uptrend in flu names; NitroMed exec exits applauded; BioMarin off on deals
|
3/16/2006 | BT | Generex given "going concern" warning by auditor
|
3/16/2006 | BT | Market Commentary: Novavax, Nastech flu names on a tear; BioMarin higher on trial; Elite bobs, Titan slips on PIPEs
|
3/15/2006 | BT | Generex oral insulin spray reduces HbA1c in adolescents with type 1 diabetes
|
3/14/2006 | BT | Market Commentary: PharmAthene going public via Siga merger; Corautus crashes, deal nixed; Novavax, Generex up
|
3/8/2006 | BT | Market Commentary: Alexza IPO gets off; Cepheid off; Dyax deal seen; Elan, Biogen up; Neurocrine shakes off trial miss
|
3/8/2006 | BT | Generex reports preliminary positive results with Oral-lyn in juvenile patients
|
2/28/2006 | BT | Market Commentary: Generex recoils along with most flu names; King Pharma clubbed; Elan, Biogen hit by analyst poll
|
2/28/2006 | BTPP | Generex Biotechnology accelerates expiry on warrants issued in 2005
|
2/27/2006 | BT | Market Commentary: Novavax bags $20 million, up 12%; BioCryst, Generex, Gilead also take flight; Cerus deal emerges
|
2/13/2006 | BT | Market Commentary: Amgen up after-hours as $4 billion convert emerges; Genentech off; Adolor down on deal; Alnylam up
|
2/13/2006 | BT | Generex has "positive" meeting with FDA on avian flu vaccine
|
1/25/2006 | BT | Generex says interim trial results show breast cancer drug safe
|
1/24/2006 | BTPP | Generex accelerates expiry of warrants from September, December 2005 AIRs
|
1/23/2006 | BT | Generex subsidiary to file New Drug Application for avian flu vaccine
|
1/20/2006 | BTPP | New Issue: Generex raises $4 million from exercise of additional investment rights
|
1/10/2006 | BT | Generex begins new trial of Ora-Lyn insulin spray in adults with type-1 diabetes
|
1/9/2006 | BT | Generex starts study of Oral-lyn insulin spray in teenage patients with type-1 diabetes
|
1/5/2006 | BT | Generex granted another patent for RapidMist, expands protection of device
|
1/4/2006 | BT | Generex: Metformin gum shows promise as an alternative drug delivery tool
|
12/6/2005 | BT | Generex's oral insulin spray Oral-lyn available in Ecuador in early 2006
|
12/5/2005 | BTPP | New Issue: Generex raises $3.5 million from exercise of additional investment rights
|
11/15/2005 | BT | Generex back in compliance with Nasdaq standards
|
11/4/2005 | BT | Generex hybrid peptides show promising Avian flu vaccine applications
|
10/31/2005 | BTPP | New Issue: Generex Biotechnology raises additional $500,000 from exercise of AIRs
|
10/19/2005 | BT | Generex Biotechnology to accelerate avian flu vaccine development
|
10/19/2005 | BT | Market Commentary: Predix IPO on deck; Indevus up; Generex up; NeoPharm gains; Amgen plunges; Genta climbs
|
9/9/2005 | BTPP | Investors in 2004 Generex debenture offering exercise, receive amended additional investment rights
|
6/16/2005 | BTPP | New Issue: Generex prices $2 million convertible debentures
|
11/10/2004 | PP | New Issue: Generex gets agreements for $4 million in private placement of debentures
|
11/10/2004 | PP | Market Commentary: Private placement volume strengthens on better oil prices; Inhibitex closes $50 million deal
|